Evaluation of Safety and Efficacy of FolateScan in Suspected Ovarian or Endometrial Cancer
This study aims to evaluate the safety and effectiveness of FolateScan in diagnosing suspected ovarian or endometrial cancer.
Tc 99m EC20
Urogenital Diseases+15
+ Genital Diseases
+ Adnexal Diseases
Other Study
Summary
Study start date: August 1, 2001
Actual date on which the first participant was enrolled.The study is designed to verify product safety, determine optimal imaging time, gather efficacy data for the radioactive drug product (Technetium Tc 99m EC20), and assay masses for presence of folate receptors, in women with suspected ovarian or endometrial cancer. Twelve subjects will be enrolled, with a minimum of five malignant cases, as determined by histopathological evaluation. Women with a suspected ovarian or endometrial mass who either 1) have fixed, paraffin embedded tissue sample(s) available for immunohistochemical staining obtained from a previous pathological evaluation or 2) are scheduled for a procedure to obtain tissue for pathological evaluation that can be fixed and paraffin embedded for immunohistochemical staining are eligible for this study. The ovarian mass may be either an initial finding, e.g., found at a routine pelvic examination or to investigate symptoms, or the ovarian or endometrial mass may be a finding suspicious of recurrent or residual tumor at follow-up examination after surgical resection of confirmed ovarian or endometrial cancer. Patients may not be pregnant or breastfeeding at enrollment.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.12 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Other Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Female
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: Subjects must meet the following eligibility requirements to be enrolled in the study. Subjects must be female, 18 years of age or older. Subjects must have suspected ovarian cancer or metastatic or recurrent ovarian or endometrial cancer with a known pelvic mass as diagnosed by ultrasound, MRI, or CT. Subjects either are scheduled to undergo a procedure to obtain tissue for pathological evaluation that can be fixed and paraffin embedded for immunohistochemical staining or have sufficient amounts of fixed, paraffin embedded tissue sample(s) available for immunohistochemical staining obtained from a previous pathological evaluation. Subjects must provide written informed consent prior to enrollment. Subjects must have kidney function with a creatinine value <2.0 mg/dL (within the previous 30 days). Exclusion Criteria: Subjects must be excluded if any of the following conditions are present: Subject is pregnant or breast-feeding. Subject is simultaneously participating in another investigative drug study. Subject has completed the follow-up phase of any previous study less than 30 days prior to enrollment in this study. Subject is unable to tolerate conditions for radionuclide imaging. Subject has been administered another radiopharmaceutical that would interfere with the assessment of Technetium Tc 99m EC20.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Indiana University Medical Center
Indianapolis, United StatesOpen Indiana University Medical Center in Google Maps